Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
New global analysis across five cities shows inequities in adult immunisation uptake, signalling need to redesign local and national policy interventions
Findings to be presented at the Global Coalition on Aging’s Silver Economy Forum 2023.
Download (PDF, 162.6KB) -
New global survey finds widespread misunderstandings about shingles despite its lifetime prevalence
A new GSK survey shows a large number of adults do not understand how shingles may be triggered.
Download (PDF, 256.2KB) -
GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep in relapsed/refractory multiple myeloma
Blenrep plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex.
Download (PDF, 227.8KB) -
GSK announces major step towards sustainability ambitions with advancement of low carbon Ventolin programme to Phase III trials
Next-generation propellant technology has the potential to reduce greenhouse gas emissions from Ventolin (salbutamol) inhaler.
Download (PDF, 194.3KB) -
GSK receives positive CHMP opinion recommending momelotinib for myelofibrosis patients with anaemia
Decision on EU marketing authorisation expected for momelotinib by early 2024.
Download (PDF, 206.5KB) -
Strong year-to-date and Q3 performance drives upgrade to full-year guidance
Q3 2023 performance highlights
Download (PDF, 804.7KB) -
GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen
GSK plc and Arrowhead Pharmaceuticals Inc. today announced that they have reached an agreement with Janssen Pharmaceuticals, Inc.
Download (PDF, 234.7KB) -
Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer
Statistically significant and clinically meaningful overall survival benefit observed in the overall population in the trial.
Download (PDF, 503.6KB) -
GSK launches £6m programme to boost STEM career progression for young people from under-represented groups in the UK
GSK to invest £6m in STEM equity-focused initiatives in the UK over ten years to tackle barriers to entry in STEM careers.
Download (PDF, 208.2KB) -
ViiV Healthcare receives approval from China’s National Medical Products Administration (NMPA) for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine), the first and only complete long-acting HIV-1 injectable treatment
The complete long-acting regimen enables virologically suppressed people living with HIV in China to reduce treatment dosing days.
Download (PDF, 217.9KB) -
New data for Arexvy, GSK’s RSV vaccine, show potential to help protect adults aged 50 to 59 at increased risk for RSV disease
Preliminary results from phase III trial show primary endpoints met, with non-inferior immune responses observed in adults aged 50-59.
Download (PDF, 245.6KB) -
GSK enters exclusive license agreement with Hansoh for HS-20089
Hansoh’s HS-20089 complements GSK’s portfolio of gynaecologic cancer therapies.
Download (PDF, 188.0KB) -
ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023
Key data to be presented include long-term and real-world data, including long-acting and 2-drug regimens.
Download (PDF, 274.3KB) -
GSK highlights new data in non-small cell lung cancer and endometrial cancer at the European Society for Medical Oncology (ESMO) Congress 2023, reinforcing potential of Jemperli (dostarlimab) as a backbone immuno-oncology therapy
Late-breaking data from head-to-head PERLA trial shows favourable numerical trend in overall survival (OS) results
Download (PDF, 691.5KB) -
GSK receives positive CHMP opinion recommending approval of Jemperli (dostarlimab) plus chemotherapy as a new frontline treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer
Decision on EU marketing authorisation expected by the end of the year.
Download (PDF, 598.6KB) -
GSK presents scientific advances to improve patient outcomes at the American Association for the Study of Liver Diseases’ The Liver Meeting® 2023
New data from the B-Together phase IIb trial contribute to the development of a functional cure for people living with CHB.
Download (PDF, 274.6KB) -
Statement: Zantac (ranitidine) litigation
GSK today confirmed it has reached a confidential settlement in the Cantlay/Harper case filed in California state court.
-
GSK and ViiV Healthcare to present scientific advancements in their industry-leading infectious diseases portfolio at IDWeek 2023
First scientific presentation of RSV vaccine efficacy and safety data over two seasons.
Download (PDF, 347.6KB) -
GSK and Zhifei announce exclusive strategic vaccine partnership in China
Partnership will significantly extend availability of Shingrix in China with co-promotion to healthcare professionals.
Download (PDF, 238.5KB) -
GSK survey finds parents know less about meningitis compared to some other childhood diseases
New multi-country survey finds 93% of parents couldn’t identify all three of the most common meningitis symptoms.
Download (PDF, 233.9KB)
